Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA drug recalls in 2022

Every FDA drug recall initiated in 2022, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

1,390 recalls, newest first.

Class II · Moderate risk

Dutasteride 0.1%

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0185-2023
Class II · Moderate risk

Epi-Caine

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Terminated Failed specification Pine Pharmaceuticals, LLC NDC 69194-0948-1 D-0130-2023
Class II · Moderate risk

Glycopyrrolate Tablets

Failed impurities/degradation specifications: Out of specification for unknown impurities.

Completed Impurity / degradation Avkare LLC NDC 50268-363-15 D-0091-2023
Class III · Low risk

Timolol Maleate Ophthalmic Solution

Failed Stability Specifications: Out of specification for weight loss at the 18-month stability timepoint and projected weight loss of 21.1% at shelf life.

Terminated Stability / shelf life Apotex Corp. NDC 60505-1005-4 D-0093-2023
Class I · High risk

Epinephrine

Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product

Terminated Failed specification Spectrum Laboratory Products, Inc. D-0180-2023
Class I · High risk

Epinephrine

Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product

Terminated Failed specification Spectrum Laboratory Products, Inc. D-0179-2023
Class II · Moderate risk

Ganciclovir for Injection

Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

Terminated Labeling / mix-up Hikma Pharmaceuticals USA Inc. NDC 0143-9299-01 D-0090-2023
Class II · Moderate risk

Rifampin Capsules USP

Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-659-06 D-0100-2023
Class II · Moderate risk

Menastil

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. NDC 66233-711-01 D-0084-2023
Class II · Moderate risk

ProSirona

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. NDC 66233-712-01 D-0083-2023
Class II · Moderate risk

Neuroquell

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. D-0082-2023
Class II · Moderate risk

Neuroquell Plus

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. D-0081-2023

Recalls by year